[{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Fortress Biotech","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Isotretinoin","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Journey Medical Corporation \/ Fortress Biotech","highestDevelopmentStatusID":"15","companyTruncated":"Journey Medical Corporation \/ Fortress Biotech"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"DFD-29","moa":"Protein Biosynthesis","graph1":"Dermatology","graph2":"Phase III","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Journey Medical Corporation \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Journey Medical Corporation \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"DFD-29","moa":"Protein Biosynthesis","graph1":"Dermatology","graph2":"Phase III","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Journey Medical Corporation \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Journey Medical Corporation \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Journey Medical Corporation \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Journey Medical Corporation \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Journey Medical Corporation \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Journey Medical Corporation \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Journey Medical Corporation \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Journey Medical Corporation \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Journey Medical Corporation \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Journey Medical Corporation \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Journey Medical Corporation \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Journey Medical Corporation \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Journey Medical Corporation \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Journey Medical Corporation \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Journey Medical Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Journey Medical Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Journey Medical Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Journey Medical Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Journey Medical Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Journey Medical Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Journey Medical Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Journey Medical Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Journey Medical Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Journey Medical Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"SWK Holdings Corporation","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Journey Medical Corporation \/ SWK Holdings Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Journey Medical Corporation \/ SWK Holdings Corporation"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Journey Medical Corporation \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Journey Medical Corporation \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Undisclosed","graph2":"Phase I","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Journey Medical Corporation \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"Journey Medical Corporation \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Glycopyrronium Tosylate","moa":"Muscarinic acetylcholine receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Wipes","sponsorNew":"Journey Medical Corporation \/ Journey Medical Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Journey Medical Corporation \/ Journey Medical Corporation"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Maruho","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Glycopyrronium Tosylate","moa":"Muscarinic acetylcholine receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Journey Medical Corporation","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.01,"dosageForm":"Topical Wipes","sponsorNew":"Journey Medical Corporation \/ Maruho","highestDevelopmentStatusID":"15","companyTruncated":"Journey Medical Corporation \/ Maruho"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"VYNE Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Divestment","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Journey Medical Corporation","amount2":0.47999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.47999999999999998,"dosageForm":"Topical Foam","sponsorNew":"Journey Medical Corporation \/ Journey Medical Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Journey Medical Corporation \/ Journey Medical Corporation"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Journey Medical Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Journey Medical Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Journey Medical Corporation \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Journey Medical Corporation \/ Dr. Reddy's Laboratories"}]
Find Clinical Drug Pipeline Developments & Deals by Journey Medical Corporation
Details :
FDA has approved Emrosi (minocycline hydrochloride extended release capsules), formerly referred to as DFD-29, for the treatment of inflammatory lesions of rosacea in adults.
Details :
DFD-29 (minocycline hydrochloride) has anti-inflammatory properties independent of antibacterial activity. It is being evaluated for treating papulopustular rosacea.
Details :
The funding will support anticipated expenses for DFD-29 (minocycline hydrochloride), developed for treating rosacea, including an upcoming NDA submission and preparation for its potential launch.
Details :
DFD-29 (minocycline hydrochloride modified release capsules) was developed using Multiple Unit Pellet System technology, which is being investigated for the treatment of papulopustular rosacea.
Details :
DFD-29 (minocycline hydrochloride modified release capsules) has anti-inflammatory properties independent of their antibacterial activity that correlate with certain aspects of the pathophysiology. It is currently being investigated for the treatment of ...
Details :
DFD-29 (minocycline) has anti-inflammatory properties independent of their antibacterial activity that correlate with certain aspects of the pathophysiology. It is currently being investigated for the treatment of papulopustular rosacea.
Details :
DFD-29 (minocycline hydrochloride modified release capsules) was developed using Multiple Unit Pellet System technology, which is being investigated for the treatment of papulopustular rosacea.
Details :
DFD-29 (minocycline hydrochloride) has anti-inflammatory properties independent of their antibacterial activity that correlate with certain aspects of the pathophysiology. It is being evaluated in phase 3 trials for the treatment of papulopustular rosace...
Details :
DFD-29 (minocycline) has anti-inflammatory properties independent of their antibacterial activity that correlate with certain aspects of the pathophysiology. It is currently being investigated for the treatment of papulopustular rosacea.
Details :
DFD-29 (minocycline hydrochloride modified release capsules) was developed using Multiple Unit Pellet System technology, which is being investigated for the treatment of papulopustular rosacea.